Medicare pays the ASP plus 8% (rather than 6%) of the reference biological for a 5-year period for certain biosimilar biological products

In late January, a community health center began offering an outpatient infusion clinic for administering an antibody treatment called BAM that is looked at as a means to give hope to those infected with the virus, especially as vaccine rollout is still taking time…

This year has posed some new challenges in the medical industry with immunocompromised patients concerned about their health due to Covid-19. Independent infusion service providers empower these at-risk patients to administer their medication in the home setting or at an infusion center.

COVID-19 infusion treatments were authorized by the Food and Drug Administration for emergency use against COVID-19 back in November to impede disease progression and prevent hospitalization for patients.